Featured Publications
IRF8 in Conjunction With CD123 and CD20 to Distinguish Lupus Erythematosus Panniculitis From Subcutaneous Panniculitis-like T-Cell Lymphoma
Wong J, Roy S, McNiff J, Xu M. IRF8 in Conjunction With CD123 and CD20 to Distinguish Lupus Erythematosus Panniculitis From Subcutaneous Panniculitis-like T-Cell Lymphoma. The American Journal Of Surgical Pathology 2023, 47: 1425-1431. PMID: 37767989, DOI: 10.1097/pas.0000000000002133.Peer-Reviewed Original ResearchConceptsSubcutaneous panniculitis-like T-cell lymphomaLupus erythematosus panniculitisPanniculitis-like T-cell lymphomaCase of SPTCLT-cell lymphomaPlasmacytoid dendritic cell differentiationPlasmacytoid dendritic cellsExpression of IRF8Dendritic cell differentiationCharacteristic curve analysisImportant clinical implicationsRegulatory factor 8Dendritic cellsCutaneous biopsyLymphoid aggregatesDiagnostic challengeImmunohistochemical panelImmunohistochemical expressionCD123CD20Distinct patientsClinical implicationsSubcutaneous fatDiagnostic testsPositive markersTissue-based chimerism analysis enhances detection of donor-derived neoplasia in allogeneic stem cell transplant patients
Baraban E, Hu S, Hui P, Podoltsev N, Cooper D, Xu M. Tissue-based chimerism analysis enhances detection of donor-derived neoplasia in allogeneic stem cell transplant patients. Bone Marrow Transplantation 2016, 52: 634-637. PMID: 27991892, DOI: 10.1038/bmt.2016.332.Peer-Reviewed Original ResearchEmerging Immunohistochemical Biomarkers for Myeloid Neoplasms.
Verma A, Xu ML. Emerging Immunohistochemical Biomarkers for Myeloid Neoplasms. Archives Of Pathology & Laboratory Medicine 2022, 147: 403-412. PMID: 35533352, DOI: 10.5858/arpa.2021-0558-ra.Peer-Reviewed Original ResearchConceptsMyeloid neoplasmsImmunohistochemical biomarkersImmunohistochemical markersManagement of patientsNovel immunohistochemical markerPosttreatment biopsiesImmunohistochemical toolsDisease progressionCorrect diagnosisClinical scenariosNeoplasmsPatient careLiterature searchRelevant biomarkersBiomarkersImmunohistochemistryMolecular biomarkersScientific literature searchMarkersArchival samplesOriginal articlesMolecular eraCurrent eraPatientsBiopsyGlobal assessment of IRF8 as a novel cancer biomarker
McQuaid DC, Panse G, Wang WL, Pinkus GS, Katz SG, Xu ML. Global assessment of IRF8 as a novel cancer biomarker. Human Pathology 2022, 122: 1-10. PMID: 35085599, PMCID: PMC10621657, DOI: 10.1016/j.humpath.2022.01.004.Peer-Reviewed Original ResearchConceptsBlastic plasmacytoid dendritic cell neoplasmInterferon regulatory factor 8Myeloid sarcomaDifferential diagnosisPlasmacytoid dendritic cell neoplasmDesmoplastic small round cell tumorSmall round cell tumorTriple-negative breast cancerStrong uniform expressionDendritic cell neoplasmBroad differential diagnosisNegative breast cancerRound cell tumorAbsence of CD34IHC expression patternsAcute monocytic leukemiaNovel immunohistochemical markerTypes of cancerRegulatory factor 8Cancer Genome AtlasNovel cancer biomarkersRetrospective studySynovial sarcomaCell tumorsPleomorphic sarcomaExpression of CD30 as a biomarker to predict response to brentuximab vedotin
Xu ML, Acevedo-Gadea C, Seropian S, Katz SG. Expression of CD30 as a biomarker to predict response to brentuximab vedotin. Histopathology 2016, 69: 155-158. PMID: 26648051, PMCID: PMC7064871, DOI: 10.1111/his.12914.Peer-Reviewed Original ResearchEpithelioid trophoblastic tumor: comparative genomic hybridization and diagnostic DNA genotyping
Xu ML, Yang B, Carcangiu ML, Hui P. Epithelioid trophoblastic tumor: comparative genomic hybridization and diagnostic DNA genotyping. Modern Pathology 2008, 22: 232-238. PMID: 18820674, DOI: 10.1038/modpathol.2008.165.Peer-Reviewed Original ResearchMeSH KeywordsAdultCarcinoma, Squamous CellComparative Genomic HybridizationDiagnosis, DifferentialEndometrial NeoplasmsEpithelioid CellsFemaleGene Expression Regulation, NeoplasticGenetic TestingGenotypeGestational Trophoblastic DiseaseHumansItalyLung NeoplasmsMiddle AgedPregnancyUnited StatesUterine Cervical NeoplasmsConceptsEpithelioid trophoblastic tumorTrophoblastic tumorSquamous cell carcinomaUterine cervixComparative genomic hybridizationCommon squamous cell carcinomaChromosomal alterationsInvasive squamous cell carcinomaChorionic-type intermediate trophoblastGestational trophoblastic diseaseGenomic hybridizationDNA genotypingIntermediate trophoblastTrophoblastic diseaseAnatomic locationComparative genomic hybridization analysisTrophoblastic originTumorsGenomic hybridization analysisCervixNormal tissuesTrophoblastic natureConventional comparative genomic hybridizationCarcinomaChromosomal profileDendritic Cell Markers and PD-L1 are Expressed in Mediastinal Gray Zone Lymphoma
Pelland K, Mathews S, Kamath A, Cohen P, Hudnall SD, Cotta CV, Xu ML. Dendritic Cell Markers and PD-L1 are Expressed in Mediastinal Gray Zone Lymphoma. Applied Immunohistochemistry & Molecular Morphology 2018, 26: e101-e106. PMID: 29189264, DOI: 10.1097/pai.0000000000000615.Peer-Reviewed Original ResearchConceptsPrimary mediastinal large B-cell lymphomaMediastinal gray zone lymphomaClassic Hodgkin lymphomaGray zone lymphomaPD-L1Mediastinal large B-cell lymphomaLarge B-cell lymphomaDendritic cell markersB-cell lymphomaCell gene expression profilesHodgkin's lymphomaRare entityCD123LymphomaTherapeutic potentialCell markersTherapeutic significanceGenetic featuresGene expression profilesFascinRepresentative sectionsExpression profilesImmunohistochemistryTumorsDiagnosisHistopathologic and Machine Deep Learning Criteria to Predict Lymphoma Transformation in Bone Marrow Biopsies.
Irshaid L, Bleiberg J, Weinberger E, Garritano J, Shallis RM, Patsenker J, Lindenbaum O, Kluger Y, Katz SG, Xu ML. Histopathologic and Machine Deep Learning Criteria to Predict Lymphoma Transformation in Bone Marrow Biopsies. Archives Of Pathology & Laboratory Medicine 2021, 146: 182-193. PMID: 34086849, DOI: 10.5858/arpa.2020-0510-oa.Peer-Reviewed Original ResearchConceptsLarge cell transformationChronic lymphocytic leukemiaBone marrow biopsyMarrow biopsyFollicular lymphomaIndolent B-cell lymphomaLarge lymphoma cellsClinical disease progressionDiagnosis of FLFinal outcome dataB-cell lymphomaLarge tumor cellsEase of procedureAggressive chemotherapyLow morbidityLymph nodesWorse prognosisWhole slide scansHistologic findingsPatient's probabilityDisease progressionLymphocytic leukemiaLymphoma transformationClinical questionsOutcome data
2024
Liquid biopsy‐based circulating tumour (ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable results
Mata D, Lee J, Shanmugam V, Marcus C, Schrock A, Williams E, Ritterhouse L, Hickman R, Janovitz T, Patel N, Kroger B, Ross J, Mirza K, Oxnard G, Vergilio J, Elvin J, Benhamida J, Decker B, Xu M. Liquid biopsy‐based circulating tumour (ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable results. Histopathology 2024, 84: 1224-1237. PMID: 38422618, DOI: 10.1111/his.15168.Peer-Reviewed Original ResearchConceptsNon-Hodgkin's lymphomaPlasma-cell neoplasmsAcute myeloid leukemiaCirculating tumor DNAHodgkin lymphomaMyelodysplastic syndromeHaematopoietic neoplasmsNext-generation sequencingTissue-based NGSMaximum somatic allele frequencyFoundationOne Liquid CDxTherapy-resistant clonesRelevant genomic alterationsPositive percent agreementPotential clinical utilityLymphoid malignanciesTumor DNAMyeloid leukemiaPlasma-cellsTissue biopsiesGenomic alterationsPathogenic alterationsLiquid biopsyMolecular profilingTP53Genetics and pathologic landscape of lineage switch of acute leukemia during therapy
Zhou T, Curry C, Khanlari M, Shi M, Cui W, Peker D, Chen W, Wang E, Gao J, Shen Q, Xie W, Jelloul F, King R, Yuan J, Wang X, Zhao C, Obiorah I, Courville E, Nomura E, Cherian S, Xu M, Burack W, Liu H, Jabbour E, Takahashi K, Wang W, Wang S, Khoury J, Medeiros L, Hu S. Genetics and pathologic landscape of lineage switch of acute leukemia during therapy. Blood Cancer Journal 2024, 14: 19. PMID: 38272888, PMCID: PMC10810851, DOI: 10.1038/s41408-024-00983-2.Peer-Reviewed Original Research
2023
An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS
Stahl M, Abdel-Wahab O, Wei AH, Savona MR, Xu ML, Xie Z, Taylor J, Starczynowski D, Sanz GF, Sallman DA, Santini V, Roboz GJ, Patnaik MM, Padron E, Odenike O, Nazha A, Nimer SD, Majeti R, Little RF, Gore S, List AF, Kutchroo V, Komrokji RS, Kim TK, Kim N, Hourigan CS, Hasserjian RP, Halene S, Griffiths EA, Greenberg PL, Figueroa M, Fenaux P, Efficace F, DeZern AE, Della Porta MG, Daver NG, Churpek JE, Carraway HE, Brunner AM, Borate U, Bennett JM, Bejar R, Boultwood J, Loghavi S, Bewersdorf JP, Platzbecker U, Steensma DP, Sekeres MA, Buckstein RJ, Zeidan AM. An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS. Blood Advances 2023, 7: 2709-2714. PMID: 36260702, PMCID: PMC10333740, DOI: 10.1182/bloodadvances.2022008747.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsIRF8 may be a useful marker for blastic plasmacytoid dendritic cell neoplasm, especially with weak CD123 expression
Tang H, Panse G, Braddock D, Perincheri S, Xu M, McNiff J. IRF8 may be a useful marker for blastic plasmacytoid dendritic cell neoplasm, especially with weak CD123 expression. Journal Of Cutaneous Pathology 2023, 50: 595-600. PMID: 37082914, DOI: 10.1111/cup.14439.Peer-Reviewed Original ResearchConceptsBlastic plasmacytoid dendritic cell neoplasmPlasmacytoid dendritic cell neoplasmDendritic cell neoplasmPunch biopsy specimenBiopsy specimenCell neoplasmsCase of BPDCNUseful markerTumor cellsTCL-1 expressionAtypical mononuclear cellsBone marrow involvementDiffuse dermal infiltrateDendritic cell lineagePotential diagnostic pitfallRegulatory factor 8TCL-1BPDCN casesCD123 expressionMarrow involvementDermal infiltrateCutaneous nodulesMyelodysplastic syndromeSkin nodulesMononuclear cells
2022
Differences in classification schemata for myelodysplastic/myeloproliferative overlap neoplasms
Patnaik MM, Zeidan AM, Padron E, Platzbecker U, Sallman DA, DeZern AE, Bejar R, Sekeres M, Taylor J, Little RF, Bewersdorf JP, Kim TK, Kim N, Hourigan CS, Dela Porta MG, Stahl M, Steensma D, Xu ML, Odenike O, Carraway H, Fenaux P, Nazha A, Komrokji R, Loghavi S, Xie Z, Hasserjian R, Savona M, Bennett JM. Differences in classification schemata for myelodysplastic/myeloproliferative overlap neoplasms. Leukemia 2022, 36: 2934-2938. PMID: 36335264, DOI: 10.1038/s41375-022-01754-3.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsFinding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes
Zeidan AM, Bewersdorf JP, Buckstein R, Sekeres MA, Steensma DP, Platzbecker U, Loghavi S, Boultwood J, Bejar R, Bennett JM, Borate U, Brunner AM, Carraway H, Churpek JE, Daver NG, Della Porta M, DeZern AE, Efficace F, Fenaux P, Figueroa ME, Greenberg P, Griffiths EA, Halene S, Hasserjian RP, Hourigan CS, Kim N, Kim TK, Komrokji RS, Kutchroo V, List AF, Little RF, Majeti R, Nazha A, Nimer SD, Odenike O, Padron E, Patnaik MM, Roboz GJ, Sallman DA, Sanz G, Stahl M, Starczynowski DT, Taylor J, Xie Z, Xu M, Savona MR, Wei AH, Abdel-Wahab O, Santini V. Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes. Leukemia 2022, 36: 2939-2946. PMID: 36266326, DOI: 10.1038/s41375-022-01724-9.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsBreast implant‐associated anaplastic large‐cell lymphoma: A series of two case reports diagnosed by cytopathology
Hrones M, Harigopal M, Xu M, Abi‐Raad R. Breast implant‐associated anaplastic large‐cell lymphoma: A series of two case reports diagnosed by cytopathology. Diagnostic Cytopathology 2022, 51: e25-e27. PMID: 36066320, DOI: 10.1002/dc.25052.Peer-Reviewed Original ResearchConceptsBreast implant-associated anaplastic large cell lymphomaImplant-associated anaplastic large cell lymphomaRare T-cell lymphomaAnaplastic large cell lymphomaPeri-implant effusionT-cell lymphomaLarge cell lymphomaCommon presentationDefinite treatmentBetter prognosisCase reportCytopathologic findingsCytopathologic analysisImplant removalEarly diagnosisFluid collectionBreast implantsCytopathological examinationLymphomaReportPatientsPrognosisEffusionDiseaseDiagnosisResponse to Letter to the Editor: IRF8 is a Reliable Monoblast Marker for Acute Monocytic Leukemias but does not Discriminate Between Monoblasts and Plasmacytoid Dendritic Cells
Xu ML, Katz SG. Response to Letter to the Editor: IRF8 is a Reliable Monoblast Marker for Acute Monocytic Leukemias but does not Discriminate Between Monoblasts and Plasmacytoid Dendritic Cells. The American Journal Of Surgical Pathology 2022, 46: 1739-1739. PMID: 36040049, DOI: 10.1097/pas.0000000000001961.Peer-Reviewed Original ResearchSpatial profiling of chromatin accessibility in mouse and human tissues
Deng Y, Bartosovic M, Ma S, Zhang D, Kukanja P, Xiao Y, Su G, Liu Y, Qin X, Rosoklija GB, Dwork AJ, Mann JJ, Xu ML, Halene S, Craft JE, Leong KW, Boldrini M, Castelo-Branco G, Fan R. Spatial profiling of chromatin accessibility in mouse and human tissues. Nature 2022, 609: 375-383. PMID: 35978191, PMCID: PMC9452302, DOI: 10.1038/s41586-022-05094-1.Peer-Reviewed Original ResearchConceptsChromatin accessibilityATAC-seqSpecific epigenetic landscapesChromatin accessibility profilingCell fate decisionsEpigenetic informationEpigenetic landscapeGenome scaleFate decisionsAccessible genomeCell identityEpigenetic underpinningsNext-generation sequencingGene regulatorsCell statesMouse embryosSpatial biologySpatial transcriptomicsCell typesCellular levelImmune cell typesDistinct organizationHuman tissuesProfilingSpatial profilingHuman herpesvirus 8-negative effusion-based large B-cell lymphoma: a distinct entity with unique clinicopathologic characteristics
Gisriel SD, Yuan J, Braunberger RC, Maracaja DLV, Chen X, Wu X, McCracken J, Chen M, Xie Y, Brown LE, Li P, Zhou Y, Sethi T, McHenry A, Hauser RG, Paulson N, Tang H, Hsi ED, Wang E, Zhang QY, Young KH, Xu ML, Pan Z. Human herpesvirus 8-negative effusion-based large B-cell lymphoma: a distinct entity with unique clinicopathologic characteristics. Modern Pathology 2022, 35: 1411-1422. PMID: 35562413, PMCID: PMC9926946, DOI: 10.1038/s41379-022-01091-x.Peer-Reviewed Original ResearchConceptsLarge B-cell lymphomaDistinct clinicopathologic characteristicsMedian overall survivalB-cell lymphomaOverall survivalClinicopathologic characteristicsPrimary effusion lymphomaHHV8 infectionLymphomatous effusionsNon-germinal center B-cell subtypeLonger median overall survivalUnique clinicopathologic characteristicsFavorable prognostic factorEpstein-Barr virusSeparate diagnostic criteriaHuman herpesvirus 8B-cell subtypeMulti-institutional studyNon-Japanese casesDiagnostic uniformityImmunocompetent patientsPericardial effusionPericardial involvementSelect patientsChemotherapy administrationBest Practices in CD30 Immunohistochemistry Testing, Interpretation, and Reporting: An Expert Panel Consensus.
Gru AA, Lim MS, Dogan A, Horwitz SM, Delabie J, Fu K, Peker D, Reddy VVB, Xu ML, Vij K, Slack GW, Miranda RN, Jagadeesh D, Lisano JM, Hsi ED, Torlakovic E. Best Practices in CD30 Immunohistochemistry Testing, Interpretation, and Reporting: An Expert Panel Consensus. Archives Of Pathology & Laboratory Medicine 2022, 147: 79-86. PMID: 35472771, DOI: 10.5858/arpa.2021-0270-oa.Peer-Reviewed Original ResearchConceptsCD30 expressionPeripheral T-cell lymphomaClassic Hodgkin lymphomaT-cell lymphomaDifferential diagnostic considerationsHematologists/oncologistsExpert panel consensusCD30 positivityHodgkin's lymphomaPredictive biomarkersDiagnostic workupImmunohistochemistry testingLymphoma biopsiesTherapeutic decisionsDiagnostic considerationsCD30 immunohistochemistryConsensus recommendationsPanel consensusLymphomaPositive expressionBest practice recommendationsImmunohistochemistryTumor cellsPractice recommendationsPanel recommendationsIRF8 as a Novel Marker to Differentiate Between CD30-Positive Large Cell Lymphomas
McQuaid DC, Katz SG, Xu ML. IRF8 as a Novel Marker to Differentiate Between CD30-Positive Large Cell Lymphomas. American Journal Of Clinical Pathology 2022, 158: 173-176. PMID: 35460405, PMCID: PMC10664184, DOI: 10.1093/ajcp/aqac044.Peer-Reviewed Original Research